by Raynovich Rod | Jun 7, 2021 | 2025 Rayno Biopharmaceuticals Portfolio
Update-1 6/7/21 Biogen shares soar 38% to $395 handle as trading opens late in the day. Despite mixed opinions on the efficacy and cost of the drug many analysts and executives in the industry hail the FDA approval. It should boost the industry overall and provide a...
by Raynovich Rod | Feb 15, 2021 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-2 2/17-11a…Biopharma stocks up on a down day: ABBV, AZN, BMY, MRK, VRTX with IBB off 0.5%. Update-1 Continued Sell-off in Biopharma and now Coronavirus Stocks The market was flattish with slight gains for the DOW, Financials were strong with TSY yields...
by Raynovich Rod | Nov 4, 2019 | Biopharmaceuticals
Update-1 11/5 2p EST IBB flat, NAZ up 0.185, earnings from AMRN and REGN. Amarin down 3.5% to $16.83 on earnings but bulls are waiting for label expansion. Q3 Revenues are $112.4 M up 103%, increased prescriptions for Vascepa with a 12/28/19 PADUFA date. Regeneron...
by Raynovich Rod | Mar 26, 2019 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update-3…3/29 1:15p EDT. Biotech stocks catching bids today after a choppy week of trading. We will recap our top small cap picks from the JPM Conference after the close: AMRN, GNMK and TDOC. BIIB up again to 237. CELG up over 7% as prospects for BMY deal look...
by Raynovich Rod | Mar 22, 2019 | Biopharmaceuticals
Update -2 March 24…Concerns about global growth, an inverted TSY yield curve and the German 10 year bond yield dropping below 10% triggered a major sell-off on Friday.The Russell 2000 dropped 3.62%. and the XBI dropped 4.62%. For the week ending 3/22: the XBI...
by Raynovich Rod | Jul 29, 2018 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update 7/30 at close- -Large Caps Outperform-Very Weak Tape NASDAQ continues slide down 1.39% Large Cap Leaders ABBV up 0.89%, BMY up 3.53%, CELG up 2.87%,MRK up 2%,REGN up 1.06%, VRTX up 1.35%. BIIB down 2.63%. Mid-Cap Red Screen: ACAD down 4.08%, ALNY down 7.37%,...
by Raynovich Rod | Jul 22, 2018 | Biopharmaceuticals
7/26 We will review all large cap earnings by Saturday 7/28. IBB flat to down over 5 days at $117.87; XBI down 3.2% over 5 days. Technicals do not look good. AstraZeneca (AZN) up 1.9% to $38.15 on $1B new product growth. Stock is at 2018 highs. Biogen (BIIB) stock...
by Raynovich Rod | Jul 7, 2018 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Biotech Momentum Boosted by Biogen’s Experimental Drug Biogen Has an Interesting Pipeline of Medicines for Serious Neurological Diseases Broad Biotech Rally-Green Screen Day- Even Large Caps Biotech momentum picked up on Friday after a brief sell-off in late...
by Raynovich Rod | Jan 12, 2018 | Biopharmaceuticals
J.Morgan Healthcare Conference: Companies to Watch We are still reviewing 2018 J.P.Morgan Healthcare presentations for inclusion in our portfolio but here are two longer term opportunities to track for milestones and growth: Accelerate Diagnostics and Denali...
by Raynovich Rod | Jan 10, 2018 | Biopharmaceuticals
Sluggish Early Trading in Biotech Tracks NASDAQ Down 0.14%% Promising Year for M&A and Tax Cuts Improving Bottom Line There is a little follow-on to Tuesday’s rally bringing prices for major ETFs above where they were last week. The biotech screen reverted...
